Current Headlines

  1. In-orbit Manufacturing And Drug Development Research Among U.S. National Lab-sponsored Payloads Destined For The Space Station
    4/11/2019

    The International Space Station (ISS) U.S. National Laboratory is managing 13 separate payloads launching to the orbiting laboratory to advance basic and applied research in several disciplines

  2. Evotec And Indivumed Announce Strategic Drug Discovery Collaboration On Precision Medicine For Colorectal Cancer
    4/11/2019

    Evotec SE and Indivumed GmbH announced recently that they have entered into a research collaboration to discover and develop first-in-class therapeutics for the treatment of colorectal cancer (“CRC”)

  3. HitGen And Kaken Enter Into License Agreement
    4/10/2019

    HitGen Inc. announced recently that HitGen Inc. and Kaken Pharmaceutical Co., Ltd. have entered into a license agreement to develop a novel class of drugs

  4. New Cancer Drug Targets Accelerate Path To Precision Medicine
    4/10/2019

    In one of the largest studies of its kind, researchers used CRISPR technology to disrupt every gene in over 300 cancer models from 30 cancer types and discover thousands of key genes essential for cancer’s survival

  5. UConn Researchers See Promising Early Results In Drug Discovery Partnership With AI Biotech Company
    4/9/2019

    A half dozen University of Connecticut (UConn) researchers are now working to identify potential new drugs to treat a wide range of diseases and conditions through a unique partnership that offers access to cutting-edge artificial intelligence (AI) technology and screening compounds at no cost

  6. SomaLogic Announces New Collaboration With Janssen Research & Development
    4/9/2019

    SomaLogic, Inc. announced today that it has entered into a collaborative agreement with Janssen Research & Development, LLC, one of the Janssen Pharmaceutical Companies of Johnson & Johnson. Under the agreement terms, SomaLogic will analyze ~5000 proteins in each of at least 15,000 clinical samples from Janssen to identify and validate protein biomarkers for use by Janssen and SomaLogic in predicting, diagnosing, monitoring, and treating disease

  7. Moleculin Announces Successful Expansion Of Its Leukemia Drug Program
    4/9/2019

    Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced it has successfully expanded the clinical supply of Annamycin for its on-going clinical trials via BSP Pharmaceuticals S.p.A. (www.bsppharmaceuticals.com) in Latina, Italy

  8. Open Source Drug Research Could Open Up Medicine
    4/9/2019

    Universal access to medicine could come via open source drug discovery, argues lecturer Dr Alice Motion. She works to make drug discovery less secretive, so that more people can help find the pharmaceuticals the world needs

  9. PhaseBio Receives FDA Breakthrough Therapy Designation For PB2452 For The Reversal Of The Antiplatelet Activity Of Ticagrelor
    4/8/2019

    PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for orphan diseases, today announced that the U.S. Food and Drug Administration (“FDA”) has granted Breakthrough Therapy designation for PB2452, a novel reversal agent for the antiplatelet drug ticagrelor

  10. FDA Approves First Two-Drug Complete Regimen For HIV-Infected Patients Who Have Never Received Antiretroviral Treatment
    4/8/2019

    The U.S. Food and Drug Administration today approved Dovato (dolutegravir and lamivudine), as a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults with no antiretroviral treatment history and with no known or suspected substitutions associated with resistance to the individual components of Dovato